MM promotes exit signals, driving effector NK cells outside BM via CXCR3 ligand upregulation and CXCL12 downmodulation, therefore weakening the antitumor immune response at the primary site of tumor growth. This evidence concerns the gene CXCR3 and Miyoshi myopathy.